Uncategorized
NewLimit snags $435M after seeing age reversal in human liver cells
NewLimit snags $435M after seeing age reversal in human liver cells
NewLimit is pressing the gas, speeding into clinical trials much sooner than expected after lab research showed its epigenetic reprogramming asset reversed aging in human liver cells. Read More